These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21911570)

  • 1. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
    Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
    Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
    Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.
    Friberg LE; Ravva P; Karlsson MO; Liu P
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3032-42. PubMed ID: 22430956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
    Walsh TJ; Driscoll T; Milligan PA; Wood ND; Schlamm H; Groll AH; Jafri H; Arrieta AC; Klein NJ; Lutsar I
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4116-23. PubMed ID: 20660687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
    Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
    Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.
    Mori M; Kobayashi R; Kato K; Maeda N; Fukushima K; Goto H; Inoue M; Muto C; Okayama A; Watanabe K; Liu P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1004-13. PubMed ID: 25451051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
    Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
    Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
    Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
    Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
    Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
    Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
    Crandon JL; Banevicius MA; Fang AF; Crownover PH; Knauft RF; Pope JS; Russomanno JH; Shore E; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5102-7. PubMed ID: 19770284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
    Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
    Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
    Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of voriconazole and dose individualization.
    Lutsar I; Hodges MR; Tomaszewski K; Troke PF; Wood ND
    Clin Infect Dis; 2003 Apr; 36(8):1087-8. PubMed ID: 12684928
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.